Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive <i>EGFR</i> mutations: NEJ005/TCOG0902.Satoshi Oizumi, Koichi Minato, Toshiyuki Harada et al.|Journal of Clinical Oncology|2014Cited by 6
Updated survival outcomes of NEJ005/TCOG0902, a randomized phase II study of concurrent (C) versus sequential alternating (S) gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (<i>EGFR</i>) mutations.Satoshi Oizumi, Toshihiro Nukiwa, Shunichi Sugawara et al.|Journal of Clinical Oncology|2017Cited by 4